Dyne Therapeutics (DYN) Equity Ratio (2019 - 2026)

Dyne Therapeutics' Equity Ratio history runs 8 years deep, the most recent figure standing at 0.8 for Q1 2026.

• In Q1 2026, Equity Ratio fell 13.66% year-over-year to 0.8; the TTM figure through Mar 2026 stood at 0.8 (down 13.66% YoY), while the FY2025 annual figure was 0.82, down 10.12% from the prior year.
• Equity Ratio was 0.8 for Q1 2026 at Dyne Therapeutics, down from 0.82 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.94 in Q2 2024 to a low of 0.55 in Q4 2023.
• Historically, Equity Ratio has averaged 0.83 across 5 years, with a median of 0.83 in 2022.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio plunged 32.87% in 2023, then surged 64.77% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.82 in 2022, then slumped by 32.87% to 0.55 in 2023, then jumped by 64.77% to 0.91 in 2024, then retreated by 10.12% to 0.82 in 2025, then slipped by 2.2% to 0.8 in 2026.
• The last three Equity Ratio figures came in at 0.8 (Q1 2026), 0.82 (Q4 2025), and 0.8 (Q3 2025), per Business Quant data.